Cephalon Inc. left its comfort zone of cancer and pain, giving Ception Inc. a $100 million up-front payment for an option to buy the company and its main anti-inflammatory product for an additional $250 million-plus. (BioWorld Today)

As its Flurizan product nears what could be a multi-billion dollar market in Alzheimer's disease, Myriad Genetics Inc. launched its global strategy by signing a commercialization deal in Europe with J. Lundbeck AS for $100 million upfront with a potential for $250 million. (BioWorld Today)